[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-370703-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-370703-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","deciphering-dual-clinical-entities-associated-with-tp53-pathogenic-variants-insights-from-53085-hboc-panel-analyses-in-french-laboratories","Deciphering dual clinical entities associated with TP53 pathogenic variants - Insights from 53,085 HBOC panel analyses in French laboratories","","TP53 is included in most cancer predisposition multigene panels, especially those evaluating hereditary breast and ovarian cancer (HBOC). This study collected genotypes and phenotypes from 398 patients carrying TP53 pathogenic variants identified through 53,085 HBOC panel analyses across 15 French laboratories. Heterozygous TP53 variants were found in 0.44% of panels. Breast cancers linked to TP53 were mainly triple-positive, including Her2+ tumors, in situ cancers, and phyllodes tumors. Two TP53-associated phenotypic entities—classic Li–Fraumeni syndrome (LFS) and TP53-related breast cancer—were proposed, influenced by variant type and family-history modifiers.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/deciphering-dual-clinical-entities-associated-with-tp53-pathogenic-variants-insights-from-53085-hboc-panel-analyses-in-french-laboratories/370703/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/deciphering-dual-clinical-entities-associated-with-tp53-pathogenic-variants-insights-from-53085-hboc-panel-analyses-in-french-laboratories/370703.png","ImageObject",300,407,{"name":42,"@type":43},"Nguyễn Văn Học","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",15,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main goal of this study?","Question",{"text":63,"@type":64},"To define how TP53 pathogenic variants contribute to the HBOC phenotype using collected genotypes and phenotypes from patients identified in French laboratories through HBOC panel sequencing.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was TP53 pathogenic variant status assessed in the cohort?",{"text":68,"@type":64},"Patients were identified by 53,085 HBOC panel analyses, and heterozygous TP53 variants were classified into pathogenic variants (PV) and variants of unknown significance (VUS) based on panel results.",{"name":70,"@type":61,"acceptedAnswer":71},"What key genotype–phenotype patterns were reported?",{"text":72,"@type":64},"Breast cancers associated with TP53 were predominantly triple positive, especially Her2+ breast cancer, in situ cancer, or phyllodes tumors. The study also links null variants to the HBOC phenotype and missense variants, particularly with dominant-negative effects, to the LFS phenotype.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},370703,1790386695,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},1374402739827,"https://ap-avatar.wpscdn.com/avatar/14000c97e7351f1a627?x-image-process=image/resize,m_fixed,w_180,h_180&k=1787885694763230660","DOI: 10.1002/ijc.35475  \nRES EARCH A RTICLE  \nC a ncer Geneti cs an d E p igen e ti cs  \nDeciphering dual clinical entities associated with TP53 pathogenic variants: Insights from 53,085 HBOC panel analyses in French laboratories  \nEdwige Kasper 1  | Flavie Boulouard 2,3 | Noémie Basset 4 | Lisa Golmard 5,6 | Hela Sassi 7 | Emilie Bouvignies 1 | Maud Branchaud 1 | Camille Charbonnier 8 | Nathalie Parodi 1 | Marion Rolain 1 | Juliette Albuisson 9 | Ayman al Saati 10,11  | Patrick Benusiglio 4 | Pascaline Berthet 12 | Marie Bidart 13,14 | Céline Bonnet 15,16 | Ahmed Bouras 17,18 | Nadia Boutry-Kryza 19 | Fanny Brayotel 20 | Virginie Bubien 21 | Adrien Buisson 22 | Laurent Castéra 2,3 | Olivier Caron 23 | Chrystelle Colas 5,24 | Florence Coulet 4 | Capucine Delnatte 25,26 | Valentin Derangère 27,28 |  \nAlice Fievet 6 | Céline Garrec 25 | Marion Gauthier-Villars 5 | Mathilde Gay-Bellile 29,30 | Vincent Goussot 31 | Jessica le Gall 5 | Mathis Lepage 29,30 | Anna Lokchine 2,3 | Alexandre Perrier 4 | Etienne Rouleau 6,32 | Nicolas Sevenet 18,33  |  \nDominique Stoppa-Lyonnet 5,24,34 | Jean-Marie Ravel 15,16,35 | Pierre Vande Perre 11  | Dominique Vaur 2,3 | Paul Vilquin 36 | Gaëlle Bougeard 37 |  \nStéphanie Baert-Desurmont 1 | Jean-Christophe Thery 38 | Claude Houdayer 1  \nCorrespondence  \nEdwige Kasper, Department of Genetics, Univ Rouen Normandie, Normandie Univ, Inserm U1245, FHU G4-Genomique and CHU Rouen, F-76000 Rouen, France.  \nEmail: [edwige.kasper@chu-rouen.fr](edwige.kasper@chu-rouen.fr)  \n[Correction added on 27 June 2025, after first online publication: The first name of Hela Sassi has been corrected.]  \nAbstract  \nTP53 is included in most cancer predisposition multigene panels, especially those exploring Hereditary Breast and Ovarian Cancer (HBOC) predisposition. The purpose of this study was to define the contribution of TP53 pathogenic variants (PV) to the HBOC phenotype by collecting genotypes and phenotypes of 398 patients harboringa TP53 variant identified by 53,085 HBOC panel sequencing in 15 French laboratories. Heterozygous TP53 variants were identified in 0 .44% of HBOC panels, evenly distributed between PV and VUS. Breast cancers associated with TP53 were predominantly triple positive, particularly Her2+ breast cancer, in situ cancer, or phyllodes tumors (p \u003C 0 .0001 for both) . Interestingly, TP53 PV were identified across all ages in  \nAbbreviations: CHIP, clonal hematopoiesis of indeterminate potential; ctDNA, circulating tumor DNA; DNE, dominant-negative effect; EOBC, early-onset breast cancer; HBOC, hereditary breast and ovarian cancer; LFS, Li–Fraumeni syndrome; LOF, loss-of-function; LP, likely pathogenic; P, pathogenic; PV, pathogenic variant; VAF, variant allele frequency; VUS, variant of unknown significance.  \nFor affiliations refer to page 905  \nThis is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.  \n© 2025 The Author(s) . International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.  \nbreast cancer patients, with enrichment before 36y. We demonstrated that null variants were linked with the HBOC phenotype, and missense variants, especially with a dominant negative effect, with the LFS phenotype (p = 0.0096) . Patients with breast cancer harboring null variants displayed an earlier age of onset compared to missense (p = 0.0030) . Surprisingly, we identified, in late-onset cancer patients, TP53 hotspot PV usually identified in classic LFS, which underlines variable penetrance. Thus, this study suggests the existence of two phenotypic entities associated with TP53 PV: clinical LFS and TP53-related breast cancer. The type of TP53 variant, as well as modifying factors reflected in family history, may influence these phenotypes, and both should be considere","cbCaiizccKDSwKv3","https://ap.wps.com/l/cbCaiizccKDSwKv3","pdf",1328951,11,"English","# Abstract\n# Introduction\n## Germline TP53 and Li–Fraumeni syndrome\n## TP53 in multigene panels for HBOC predisposition","[{\"question\":\"What is the main goal of this study?\",\"answer\":\"To define how TP53 pathogenic variants contribute to the HBOC phenotype using collected genotypes and phenotypes from patients identified in French laboratories through HBOC panel sequencing.\"},{\"question\":\"How was TP53 pathogenic variant status assessed in the cohort?\",\"answer\":\"Patients were identified by 53,085 HBOC panel analyses, and heterozygous TP53 variants were classified into pathogenic variants (PV) and variants of unknown significance (VUS) based on panel results.\"},{\"question\":\"What key genotype–phenotype patterns were reported?\",\"answer\":\"Breast cancers associated with TP53 were predominantly triple positive, especially Her2+ breast cancer, in situ cancer, or phyllodes tumors. The study also links null variants to the HBOC phenotype and missense variants, particularly with dominant-negative effects, to the LFS phenotype.\"}]","Deciphering dual clinical entities associated with TP53 pathogenic variants - Insights from 53,085 HBOC panel analyses in French laboratories | PDF",1790189938,28,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f3d5be01a82bcbfcc023bcf3ad06f115.webp",983,1291,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c773e945a1b0463658cf447448993173.webp",982,1290,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f0c9c708ef025607d9894362351aef7f.webp",981,1289,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3fe38ad5c7ca00412a205d2b3f7e416c.webp",980,1287]